Accelerating Availability of New Vaccines: The Role of the International Community

  • Julie B. Milstien
  • Amie Batson


Most vaccines available to national immunization programs rely on old technologies, are produced by a wide range of laboratories, and meet a variety of standards. The world, however, is facing an explosion of new vaccine products and technologies. The challenge facing the international community is to facilitate global access to high quality, affordable vaccines against priority diseases. Strategies developed to address this challenge are targeting assistance to the neediest countries, tiering of prices for new vaccines according to a segmented market, and assuring access to new technologies for viable local producers. The international community may intervene in three major areas: vaccine development, introduction, and self-sufficiency. Necessary activities include prioritization of vaccine options based on epidemiological disease burden, coordinating research and development, minimizing risks and costs of clinical trials, and strengthening infrastructure so that countries can take responsibility for their own vaccine supply needs. The indication that these activities are being effectively managed is the degree to which new vaccines against important diseases are available in all countries for the majority of the population at risk.

Key Words

Vaccine development Immunization Harmonization Vaccine markets Vaccine financing 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Batson A, Evans P, Milstien, JB. The crisis in vaccine supply: a framework for action. Vaccine. 1994;12(11): 963–965.CrossRefGoogle Scholar
  2. 2.
    Rizzetto M, Purcell RH, Gerin JL, Verme G. Viral Hepatitis and Liver Disease. Edizioni Minerva Medica, Turin, 1997.Proceedings of IX Triennial International Symposium on Viral Hepatitis and Liver Disease. Rome, Italy, April 21–25, 1996.Google Scholar
  3. 3.
    Milstien JB, Evans P, Batson A. Discussion: Vaccine production and supply in developing countries. In: Cutts FT and Smith PG ed. Vaccination & World Health. Chichester: John Wiley & Sons; 1994:60–66.Google Scholar
  4. 4.
    Milstien JB, Gellin BG, Kane M, di Fabio JL, Homma A. Global DTP Manufacturing Capacity and Capability. Status report: January 1995. Vaccine. 1996;14(4):313–320.CrossRefGoogle Scholar

Copyright information

© Drug Information Association, Inc 1998

Authors and Affiliations

  • Julie B. Milstien
    • 1
  • Amie Batson
    • 1
  1. 1.Vaccine Supply and Quality Unit, Global Programme for Vaccines and ImmunizationWorld Health OrganizationGeneva 27Switzerland

Personalised recommendations